Most Read Articles
Popular Stories
RADAR on Medicare Advantage
-
With the last of the baby boomer generation aging into Medicare by 2030, when an estimated one in five people will be over age 65, seniors will be a driving force in health care transformation. At a recent panel...
-
Given apparent conflicts of interest that came to light in a recent New York Times article, President Donald Trump’s pick for CMS administrator, Mehmet Oz, M.D., is likely to face tough questions from Democrats in...
HEALTH PLAN WEEKLY
-
In the first Affordable Care Act regulation issued since President Donald Trump started his second term, CMS on March 10 unveiled a set of proposals that experts say would add new coverage hurdles for consumers...
-
If the enhanced subsidies of Affordable Care Act plans expire at the end of this year, multiple new studies have found that states could see millions of their residents lose health care coverage and jobs, leading to...
Radar On Speciality Pharmacy
-
The cell and gene therapy (CGT) space seems to be a bit of a mixed bag recently. While last year’s accomplishments included FDA approvals of two new first-in-class treatments for solid tumors and the first...
-
As CMS undergoes its pricing negotiations on the second round of drugs under the Medicare Drug Price Negotiation Program, a recent report reveals that manufacturer concerns over the program’s potential threat...
RADAR ON DRUG BENEFITS
-
Extending inflation-based prescription drug rebates to all commercial health plans, rather than just applying them to the Medicare program, could potentially save as much as $8.1 billion annually,...
-
A recent Institute for Clinical and Economic Review (ICER) report found that Trelegy Ellipta (fluticasone/umeclidinium/vilanterol) and Breo Ellipta (fluticasone/vilanterol), two chronic obstructive...
About AIS Health
AIS Health is a publishing and information company that has served the health care industry for more than 30 years. Our mission is to provide our readers with an actionable understanding of the business of health care and pharmaceuticals. Our in-depth writing covers the companies, people, catalysts and trends that create the richly textured contours of the health care and drug industry. AIS Health maintains journalistic independence from our parent company, MMIT. We are committed to integrity in reporting and bringing transparency to health industry data.
The Latest
Complimentary Publications
Premium Categories
Premium Categories
Get an actionable understanding of the business of health care and pharmaceuticals
Sign up for publications to get unmatched business intelligence delivered to your inbox.